10 results on '"Uy, Geoffrey L."'
Search Results
2. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
- Author
-
Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang TC, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Luger SM, Mullighan CG, and Tallman MS
- Subjects
- Humans, Adult, Middle Aged, Male, Female, Aged, Consolidation Chemotherapy, Remission Induction, Disease-Free Survival, Kaplan-Meier Estimate, Survival Analysis, Recurrence, Antineoplastic Agents therapeutic use, Antineoplastic Agents adverse effects, Induction Chemotherapy, Antibodies, Bispecific adverse effects, Antibodies, Bispecific therapeutic use, Antibodies, Bispecific administration & dosage, Neoplasm, Residual, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma mortality, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects
- Abstract
Background: Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)-negative complete remission with combination chemotherapy. The addition of blinatumomab, a bispecific T-cell engager molecule that is approved for the treatment of relapsed, refractory, and MRD-positive BCP-ALL, may have efficacy in patients with MRD-negative remission., Methods: In a phase 3 trial, we randomly assigned patients 30 to 70 years of age with BCR::ABL1 -negative BCP-ALL (with :: indicating fusion) who had MRD-negative remission (defined as <0.01% leukemic cells in bone marrow as assessed on flow cytometry) after induction and intensification chemotherapy to receive four cycles of blinatumomab in addition to four cycles of consolidation chemotherapy or to receive four cycles of consolidation chemotherapy alone. The primary end point was overall survival, and relapse-free survival was a secondary end point., Results: The data and safety monitoring committee reviewed the results from the third efficacy interim analysis and recommended that they be reported. Complete remission with or without full count recovery was observed in 395 of 488 enrolled patients (81%). Of the 224 patients with MRD-negative status, 112 were assigned to each group. The characteristics of the patients were balanced between the groups. At a median follow-up of 43 months, an advantage was observed in the blinatumomab group as compared with the chemotherapy-only group with regard to overall survival (at 3 years: 85% vs. 68%; hazard ratio for death, 0.41; 95% confidence interval [CI], 0.23 to 0.73; P = 0.002), and the 3-year relapse-free survival was 80% with blinatumomab and 64% with chemotherapy alone (hazard ratio for relapse or death, 0.53; 95% CI, 0.32 to 0.87). A higher incidence of neuropsychiatric events was reported in the blinatumomab group than in the chemotherapy-only group., Conclusions: The addition of blinatumomab to consolidation chemotherapy in adult patients in MRD-negative remission from BCP-ALL significantly improved overall survival. (Funded by the National Institutes of Health and others; E1910 ClinicalTrials.gov number, NCT02003222.)., (Copyright © 2024 Massachusetts Medical Society.)
- Published
- 2024
- Full Text
- View/download PDF
3. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
- Author
-
Borthakur G, Ofran Y, Tallman MS, Foran J, Uy GL, DiPersio JF, Showel MM, Shimoni A, Nagler A, Rowe JM, Altman JK, Abraham M, Peled A, Shaw S, Bohana-Kashtan O, Sorani E, Pereg Y, Foley-Comer A, Oberkovitz G, Lustig TM, Glicko-Kabir I, Aharon A, Vainstein-Haras A, Kadosh SE, Samara E, Al-Rawi AN, Pemmaraju N, Bueso-Ramos C, Cortes JE, and Andreeff M
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bone Marrow Cells drug effects, Drug Administration Schedule, Drug Resistance, Neoplasm, Female, Hematopoietic Stem Cell Mobilization, Humans, Leukemia, Myeloid, Acute blood, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Peptides adverse effects, Peptides pharmacokinetics, Recurrence, Remission Induction, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Cytarabine administration & dosage, Leukemia, Myeloid, Acute drug therapy, Peptides administration & dosage, Receptors, CXCR4 antagonists & inhibitors
- Abstract
Background: CXCR4 mediates the retention and survival of acute myelogenous leukemia blasts in bone marrow and contributes to their resistance to chemotherapy. The authors evaluated a combination of the high-affinity CXCR4 antagonist BL-8040 with high-dose cytarabine (HiDAC) chemotherapy in a phase 2a study of patients with relapsed and refractory AML., Methods: Forty-two patients received treatment with BL-8040 monotherapy for 2 days followed by a combination of BL-8040 with HiDAC for 5 days. Six escalating BL-8040 dose levels were investigated (0.5, 0.75, 1.0, 1.25, 1.5, and 2.0 mg/kg), and 1.5 mg/kg was selected as the dose for the expansion phase (n = 23)., Results: BL-8040 in combination with HiDAC was safe and well tolerated at all dose levels. Clinical response was observed with BL-8040 doses ≥1.0 mg/kg. The composite response rate (complete remissions plus complete remissions with incomplete hematologic recovery of platelets or neutrophils) was 29% (12 of 42) in all patients and 39% (9 of 23) in the 1.5-mg/kg phase. The median overall survival was 8.4 months for all patients, 10.8 months in the 1.5-mg/kg phase, and 21.8 months for responding patients in the 1.5-mg/kg cohort. Two days of BL-8040 monotherapy triggered the mobilization of blasts into peripheral blood, with significantly higher mean fold-changes in responders versus nonresponders. This was accompanied by a decrease in bone marrow blasts., Conclusions: The current results demonstrate the efficacy of CXCR4 targeting with BL-8040 and support continued clinical development in acute myelogenous leukemia., (© 2020 American Cancer Society.)
- Published
- 2021
- Full Text
- View/download PDF
4. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
- Author
-
Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, and Uy GL
- Subjects
- Aged, Antineoplastic Combined Chemotherapy Protocols pharmacokinetics, Decitabine adverse effects, Decitabine pharmacokinetics, Dose-Response Relationship, Drug, Febrile Neutropenia chemically induced, Feeding and Eating Disorders chemically induced, Female, Humans, Leukemia, Myeloid, Acute pathology, Male, Molecular Targeted Therapy, Pteridines adverse effects, Pteridines pharmacokinetics, Treatment Outcome, Polo-Like Kinase 1, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cell Cycle Proteins genetics, Cell Cycle Proteins metabolism, Cell Cycle Proteins physiology, Decitabine administration & dosage, Gene Expression, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, Protein Serine-Threonine Kinases genetics, Protein Serine-Threonine Kinases metabolism, Protein Serine-Threonine Kinases physiology, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins physiology, Pteridines administration & dosage
- Abstract
Polo-like kinase 1 (PLK1) regulates mitotic checkpoints and cell division. PLK1 overexpression is reported in numerous cancers, including acute myeloid leukemia (AML), and is associated with poor prognosis. Volasertib is a selective, potent cell-cycle kinase inhibitor that targets PLK to induce mitotic arrest and apoptosis. This phase 1 trial investigated the maximum tolerated dose (MTD), safety, pharmacokinetics, and anti-leukemic activity of volasertib in combination with decitabine in AML patients aged ≥ 65 years. Thirteen patients were treated with escalating volasertib doses (3 + 3 design; 300 mg, 350 mg, and 400 mg) plus standard-dose decitabine. Dose-limiting toxicity was reported in one patient in cycle 1; the MTD of volasertib in combination with decitabine was determined as 400 mg. The most common treatment-emergent adverse events were febrile neutropenia, pneumonia, and decreased appetite. Objective response rate was 23%. The combination was well tolerated, and the adverse event profile was in line with previous findings.
- Published
- 2021
- Full Text
- View/download PDF
5. A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma.
- Author
-
Ghobadi A, Fiala MA, Rettig M, Schroeder M, Uy GL, Stockerl-Goldstein K, Westervelt P, Vij R, and DiPersio JF
- Subjects
- Aged, Antigens, CD34 metabolism, Bortezomib administration & dosage, Feasibility Studies, Female, Graft Survival drug effects, Granulocyte Colony-Stimulating Factor administration & dosage, Hematopoietic Stem Cells cytology, Hematopoietic Stem Cells metabolism, Humans, Male, Middle Aged, Outcome Assessment, Health Care methods, Outcome Assessment, Health Care statistics & numerical data, Transplantation, Autologous, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hematopoietic Stem Cell Mobilization methods, Hematopoietic Stem Cell Transplantation methods, Hematopoietic Stem Cells drug effects, Multiple Myeloma therapy
- Abstract
Background: We previously reported that administration of bortezomib (BTZ) after 4 days of granulocyte colony-stimulating factor (G-CSF) significantly augments mobilization in mice. We hypothesized that administration of BTZ at peak G-CSF mobilization in patients with multiple myeloma (MM) would be safe, augment mobilization, and have an in vivo purging effect on circulating myeloma cells., Patients and Methods: This was a phase I study using 3 dose levels of BTZ. G-CSF was administered for 5 days. On the evening of the fourth day, a single dose of BTZ was administered. Peripheral blood was drawn 1 to 2 hours before and 15 to 18 hours after BTZ administration (before day 5 G-CSF administration) to analyze the mobilization effect of BTZ. Standard apheresis was then performed starting on day 5. After mobilization, patients underwent autologous stem cell transplantation (ASCT) per institutional guidelines., Results: Ten patients were enrolled. There were no dose-limiting toxicities. Median peripheral blood CD34
+ cells at day 4 before BTZ administration was 16 per microliter and 15 hours later was 32 per microliter suggesting that administration of BTZ at peak G-CSF mobilization augments the mobilization effect of G-CSF. The effect of BTZ on circulating MM cells was unclear. All patients had successful engraftment after ASCT., Conclusion: Administration of 1 dose of BTZ at peak G-CSF mobilization was safe and well tolerated, enhanced stem cell mobilization, and did not affect graft viability. The mobilization effect of BTZ at peak G-CSF mobilization shown in this phase I study needs to be confirmed in a larger randomized trial., (Copyright © 2019 Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
6. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614).
- Author
-
Yin J, LaPlant B, Uy GL, Marcucci G, Blum W, Larson RA, Stone RM, and Mandrekar SJ
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Allografts, Anthracyclines administration & dosage, Cytarabine administration & dosage, Disease-Free Survival, Female, Humans, Induction Chemotherapy, Male, Middle Aged, Survival Rate, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute mortality, Leukemia, Myeloid, Acute therapy
- Abstract
Event-free survival (EFS) is controversial as an end point for speeding approvals in newly diagnosed acute myeloid leukemia (AML). We aimed to examine the robustness of EFS, specifically timing of complete remission (CR) in defining induction failure and impact of hematopoietic cell transplantation (HCT). The study included 1884 untreated AML patients enrolled across 5 trials conducted through Alliance for Clinical Trials in Oncology using anthracycline and cytarabine induction chemotherapy. EFS was defined as time from randomization/registration to induction failure, relapse, or death. Three definitions of induction failure were evaluated: failure to achieve CR by 60 days after randomization/registration, failure to achieve CR by the end of all protocol-defined induction courses, and failure to achieve CR by the end of all protocol-defined treatment. We considered either censoring or no censoring at time of non-protocol-mandated HCT. Although relapse and death are firm end points, the determination of induction failure was not consistent across studies. There was minimal impact of censoring at HCT on EFS estimates; however, median EFS estimates differed considerably based on the timing of CR in defining induction failure, with the magnitude of difference being large enough in most cases to lead to incorrect conclusions about efficacy in a single-arm trial, if the trial definition was not consistent with the definition used for the historical control. Timing of CR should be carefully examined in the historical control data used to guide the design of single-arm trials using EFS as the primary end point. Trials were registered at www.clinicaltrials.gov as #NCT00085124, #NCT00416598, # NCT00651261, #NCT01238211, and #NCT01253070., (© 2019 by The American Society of Hematology.)
- Published
- 2019
- Full Text
- View/download PDF
7. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
- Author
-
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, and Medeiros BC
- Subjects
- Aged, Female, Humans, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Neoplasms, Second Primary drug therapy, Neoplasms, Second Primary mortality, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cytarabine therapeutic use, Daunorubicin therapeutic use, Leukemia, Myeloid, Acute drug therapy
- Abstract
Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survival versus standard-of-care cytarabine plus daunorubicin chemotherapy (7+3 regimen) in older patients with newly diagnosed secondary acute myeloid leukemia (sAML). Patients and Methods In this open-label, randomized, phase III trial, 309 patients age 60 to 75 years with newly diagnosed high-risk/sAML received one to two induction cycles of CPX-351 or 7+3 followed by consolidation therapy with a similar regimen. The primary end point was overall survival. Results CPX-351 significantly improved median overall survival versus 7+3 (9.56 v 5.95 months; hazard ratio, 0.69; 95% CI, 0.52 to 0.90; one-sided P = .003). Overall remission rate was also significantly higher with CPX-351 versus 7+3 (47.7% v 33.3%; two-sided P = .016). Improved outcomes were observed across age-groups and AML subtypes. The incidences of nonhematologic adverse events were comparable between arms, despite a longer treatment phase and prolonged time to neutrophil and platelet count recovery with CPX-351. Early mortality rates with CPX-351 and 7+3 were 5.9% and 10.6% (two-sided P = .149) through day 30 and 13.7% and 21.2% (two-sided P = .097) through day 60. Conclusion CPX-351 treatment is associated with significantly longer survival compared with conventional 7+3 in older adults with newly diagnosed sAML. The safety profile of CPX-351 was similar to that of conventional 7+3 therapy.
- Published
- 2018
- Full Text
- View/download PDF
8. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
- Author
-
Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, and DiPersio JF
- Subjects
- Adolescent, Adult, Aged, Benzylamines, Cyclams, Cytarabine administration & dosage, Etoposide administration & dosage, Female, Flow Cytometry, Humans, Male, Middle Aged, Mitoxantrone administration & dosage, Prognosis, Remission Induction, Survival Rate, Young Adult, Anti-HIV Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Drug Resistance, Neoplasm, Heterocyclic Compounds therapeutic use, Leukemia, Myeloid, Acute drug therapy, Neoplasm Recurrence, Local drug therapy, Receptors, CXCR4 antagonists & inhibitors, Salvage Therapy
- Abstract
The interaction of acute myeloid leukemia (AML) blasts with the leukemic microenvironment is postulated to be an important mediator of resistance to chemotherapy and disease relapse. We hypothesized that inhibition of the CXCR4/CXCL12 axis by the small molecule inhibitor, plerixafor, would disrupt the interaction of leukemic blasts with the environment and increase the sensitivity of AML blasts to chemotherapy. In this phase 1/2 study, 52 patients with relapsed or refractory AML were treated with plerixafor in combination with mitoxantrone, etoposide, and cytarabine. In phase 1, plerixafor was escalated to a maximum of 0.24 mg/kg/d without any dose-limiting toxicities. In phase 2, 46 patients were treated with plerixafor 0.24 mg/kg/d in combination with chemotherapy with an overall complete remission and complete remission with incomplete blood count recovery rate (CR + CRi) of 46%. Correlative studies demonstrated a 2-fold mobilization in leukemic blasts into the peripheral circulation. No evidence of symptomatic hyperleukocytosis or delayed count recovery was observed with the addition of plerixafor. We conclude that the addition of plerixafor to cytotoxic chemotherapy is feasible in AML, and results in encouraging rates of remission with correlative studies demonstrating in vivo evidence of disruption of the CXCR4/CXCL12 axis.
- Published
- 2012
- Full Text
- View/download PDF
9. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
- Author
-
Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, Dipersio JF, and Vij R
- Subjects
- Adolescent, Adult, Aged, Aminoglycosides administration & dosage, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Humanized, Cytarabine administration & dosage, Drug Evaluation, Female, Gemtuzumab, Humans, Idarubicin administration & dosage, Male, Middle Aged, Remission Induction, Retrospective Studies, Survival Analysis, Treatment Outcome, Vidarabine administration & dosage, Vidarabine analogs & derivatives, Young Adult, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Granulocyte Colony-Stimulating Factor administration & dosage, Leukemia, Myeloid, Acute drug therapy, Salvage Therapy methods
- Abstract
The current salvage therapies for relapsed/refractory acute myeloid leukemia (AML) are unsatisfactory. Over the past 7 years, we have used two salvage regimens: fludarabine, cytarabine, and idarubicin with (FLAG-IM) or without gemtuzumab ozogamicin (GO) (9 mg/m(2) on Day 8) (FLAG-I) in relapsed/refractory AML. Three-quarters of patients also received concurrent G-CSF. Seventy-one patients were treated, 23 with FLAG-I and 48 with FLAG-IM. The median duration of follow-up was 30.6 months. The treatment groups were well balanced with median ages of 48 years (range 18-70) and 47 years (range 20-68), unfavorable cytogenetics in 57% and 35%, prior allogeneic stem cell transplant in 43% and 42%, and CR1 duration <1 year in 60% and 67%, respectively, for FLAG-I and FLAG-IM. The complete remission (CR) rate in the FLAG-I group was 39% with an additional 13% achieving a CRp [overall response rate (ORR) 52%]; the CR rate in the FLAG-IM group was 29% with an additional 27% achieving a CRp (ORR 56%). The median duration of response (DOR; 16.8 vs. 8.3 months), event-free survival (EFS; 7.4 vs. 4.1 months), and overall survival (OS; 8.8 vs. 5.0 months) trended to favor FLAG-I over FLAG-IM. The patients who received G-CSF concurrent with chemotherapy had superior overall response rate (ORR; 62% vs. 29%, P = 0.026), median EFS (6.2 vs. 3.4 months, P = 0.010), and OS (8.8 vs. 3.9 months, P = 0.004) when compared with those who sequentially received G-CSF and chemotherapy, regardless of chemotherapy regimen. The addition of GO, at this dose and schedule, to FLAG-I failed to improve the outcomes in patients with relapsed/refractory AML. The patients who received G-CSF concurrently with chemotherapy had improved outcomes. Am. J. Hematol., 2009. (c) 2009 Wiley-Liss, Inc.
- Published
- 2009
- Full Text
- View/download PDF
10. Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia
- Author
-
Martha Arellano, Patrick J. Stiff, Geoffrey L. Uy, Sarah E. Church, Norbert Vey, Marianne Santaguida, Patrick Kaminker, Ibrahim Aldoss, Erin Fehr, Michael P. Rettig, Matthew C. Foster, Maya Kostova, Patrice Chevallier, John F. DiPersio, Peter H. Sayre, Anjali S. Advani, Erica K. Anderson, Kendra Sweet, Bob Löwenberg, Matthew J. Wieduwilt, Martin Wermke, Farhad Ravandi, Jayakumar Vadakekolathu, Ezio Bonvini, Michael Byrne, Mojca Jongen-Lavrencic, Emmanuel Gyan, Matteo Carrabba, Jan K Davidson-Moncada, John E. Godwin, Laura C. Michaelis, Gerwin Huls, Fabio Ciceri, Kenneth Jacobs, Sergio Rutella, Ouiam Bakkacha, Kristen Pettit, Christian Recher, Kathy M. Tran, Teia Curtis, Stefania Paolini, Jian Zhao, Roland B. Walter, Max S. Topp, Kuo Guo, Ashkan Emadi, John Muth, Harry P. Erba, Uy, Geoffrey L, Aldoss, Ibrahim, Foster, Matthew C, Sayre, Peter H, Wieduwilt, Matthew J, Advani, Anjali S, Godwin, John E, Arellano, Martha L, Sweet, Kendra, Emadi, Ashkan, Ravandi, Farhad, Erba, Harry P, Byrne, Michael, Michaelis, Laura C, Topp, Max S, Vey, Norbert, Ciceri, Fabio, Carrabba, Matteo Giovanni, Paolini, Stefania, Huls, Gerwin, Jongen-Lavrencic, Mojca, Wermke, Martin, Chevallier, Patrice, Gyan, Emmanuel, Récher, Christian, Stiff, Patrick, Pettit, Kristen, Löwenberg, Bob, Church, Sarah, Anderson, Erica Katherine, Vadakekolathu, Jayakumar, Santaguida, Marianne T, Rettig, Michael P, Muth, John, Curtis, Teia, Fehr, Erin, Guo, Kuo, Zhao, Jian, Bakkacha, Ouiam, Jacobs, Kenneth, Tran, Kathy, Kaminker, Patrick, Kostova, Maya, Bonvini, Ezio, Walter, Roland B, Davidson-Moncada, Jan Kenneth, Rutella, Sergio, Dipersio, John F, Hematology, Stem Cell Aging Leukemia and Lymphoma (SALL), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Subjects
Male ,Myeloid ,Clinical Trials and Observations ,Salvage therapy ,Biochemistry ,Gastroenterology ,RECOMMENDATIONS ,Antineoplastic Agents, Immunological ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Antibodies, Bispecific ,CRITERIA ,Protein Interaction Maps ,MYELODYSPLASTIC SYNDROME ,Aged, 80 and over ,RECEPTOR T-CELLS ,Myeloid leukemia ,Nausea ,Hematology ,Middle Aged ,Fludarabine ,CYTARABINE ,Survival Rate ,Leukemia, Myeloid, Acute ,Cytokine release syndrome ,Leukemia ,medicine.anatomical_structure ,PHASE-II ,Female ,Immunotherapy ,FLUDARABINE ,medicine.drug ,Adult ,medicine.medical_specialty ,Maximum Tolerated Dose ,Immunology ,Dose-Response Relationship, Immunologic ,Antibodies, Monoclonal, Humanized ,DIAGNOSIS ,Drug Administration Schedule ,Internal medicine ,medicine ,Humans ,Immunologic Factors ,neoplasms ,Survival rate ,Aged ,Salvage Therapy ,business.industry ,CYTOKINE RELEASE SYNDROME ,Cell Biology ,medicine.disease ,Hematopoiesis ,Drug Resistance, Neoplasm ,Cytarabine ,BLINATUMOMAB ,business ,Follow-Up Studies - Abstract
Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure [PIF]) or relapse after
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.